Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    • News

  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    • News

  • Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    • News

  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    • News

  • dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    • News

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

Mayne Pharma Board Supports $672 Million takeover by Cosette

  • In News
  • February 24, 2025
  • Gracen Moore
Mayne Pharma Board Supports $672 Million takeover by Cosette

Cosette’s Offer Price Well In Excess of Mayne’s Last Close

Mayne Pharma (ASX:MYX) has received a takeover offer from U.S.-based Cosette Pharmaceuticals, Inc., marking a major milestone in the Australian pharmaceutical sector. The agreement, structured as a Scheme of Arrangement, will see Cosette acquire 100% of Mayne Pharma’s shares for $7.40 per share, valuing the takeover target at approximately $672 million.

The offer price represents a significant premium across multiple share price benchmarks, including a 37% increase on Mayne Pharma’s last closing price and a 57% premium to its 180-day volume-weighted average price (VWAP).

Board Supports the Takeover

Mayne Pharma’s Chair, Frank Condella, believes the deal represents a compelling opportunity for shareholders.

“We are pleased that Cosette has recognised significant value in Mayne Pharma, particularly in our women’s health and dermatology businesses,” he said. “The offer provides shareholders with the opportunity to receive cash value at a significant premium.”

The Mayne Pharma Board has unanimously recommended that shareholders vote in favour of the scheme, provided no superior proposal emerges and an independent expert confirms the offer is in the best interests of shareholders.

CEO Highlights Strategic Fit

Mayne Pharma CEO, Shawn Patrick O’Brien, sees the transaction as a validation of the company’s growth strategy.

“Attracting an offer from a strategic buyer who is active in the U.S. dermatology and women’s health markets, such as Cosette, reflects the excellent work our teams have been doing,” he said. “Having broadened our portfolio and improved patient access through a refined U.S. channel strategy, we have executed against our corporate strategies with precision.”

Strong Shareholder Support

Two of Mayne Pharma’s largest shareholders, Viburnum Funds and Bruce Mathieson, who together own 14.1% of the company, have already signalled their intention to vote in favour of the deal, barring a superior proposal.

Additionally, Rubric Capital, which holds 100% of Mayne Pharma’s Convertible Notes, has agreed to divest its notes upon the scheme’s completion at an equivalent value to the takeover price per share.

Regulatory Approvals and Next Steps

While the acquisition is fully funded, it remains subject to regulatory approvals, shareholder approval, and court approval. The scheme booklet, which will provide shareholders with additional details, including an independent expert’s assessment, will be distributed ahead of the scheme meeting, expected to take place between late April and early May 2025.

If all conditions are met, the transaction is anticipated to be completed between late May and early June 2025.

About the Buyer: Cosette Pharmaceuticals

Cosette Pharmaceuticals is a U.S.-based pharmaceutical company focused on dermatology and women’s health. The company specialises in manufacturing complex dosage forms, including topical creams, oral solutions, and suppositories. Backed by Avista Healthcare Partners and Hamilton Lane, Cosette operates out of New Jersey and North Carolina with a workforce of over 350 employees.

With its strong presence in the U.S. pharmaceutical sector, Cosette’s acquisition of Mayne Pharma is set to enhance its portfolio and expand its reach in the Australian market.

What’s Next for Investors?

Mayne Pharma shareholders are not required to take any immediate action. They will have the opportunity to vote on the scheme at the upcoming scheme meeting, with further details to be provided in the scheme booklet.

For now, all eyes will be on the regulatory approval process and the final shareholder decision that will determine the future of this planned major pharmaceutical acquisition.

  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens - July 29, 2025
  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology - July 24, 2025
  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S. - July 18, 2025
  •  
  •  
  •  
  •  
  • ASX:MYX
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    February 24, 2025, 6:22 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/ai-pharmaceutical

    Reply
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens - July 29, 2025
  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology - July 24, 2025
  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S. - July 18, 2025

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens - July 29, 2025
  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology - July 24, 2025
  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S. - July 18, 2025
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.